{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:18:32Z","timestamp":1788175112818,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the long-term (5-year) efficacy and safety of upadacitinib monotherapy compared with methotrexate (MTX) monotherapy in Japanese patients with rheumatoid arthritis who were included in the Phase 3 SELECT-EARLY study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Japanese patients were randomised 2:1:1:1 to upadacitinib 7.5, 15, or 30\u00a0mg daily, or MTX 7.5\u00a0mg\/week (titrated to \u226415\u00a0mg\/week). Efficacy assessments through Week 260 are reported as observed for patients receiving continuous upadacitinib or MTX, and by randomised group using non-responder imputation. Treatment-emergent adverse events were collected over 5\u00a0years and reported as events per 100 patient-years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 138 Japanese patients treated, 123 (89%) completed Week 48, and 121 (88%) entered the long-term extension on the study drug. Patients receiving upadacitinib had better overall long-term efficacy outcomes compared with patients receiving MTX. Similarly, treatment with upadacitinib resulted in numerically greater inhibition of structural joint progression through 5\u00a0years, relative to MTX. Higher treatment-emergent adverse event rates were observed in the 30\u00a0mg upadacitinib group compared with all other treatment groups, and no new safety signals were identified overall.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This subanalysis of the SELECT-EARLY Japanese population corroborates findings from the global study population on the long-term clinical efficacy and safety of upadacitinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roag031","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:46:08Z","timestamp":1775735168000},"page":"705-715","source":"Crossref","is-referenced-by-count":0,"title":["Upadacitinib monotherapy\n                    <i>versus<\/i>\n                    methotrexate monotherapy in methotrexate-na\u00efve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5\u00a0years in the SELECT-EARLY study"],"prefix":"10.1093","volume":"36","author":[{"given":"Tsutomu","family":"Takeuchi","sequence":"first","affiliation":[{"name":"Keio University School of Medicine , Tokyo ,","place":["Japan"]},{"name":"Saitama Medical University , Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"van Vollenhoven","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitaka","family":"Ueki","sequence":"additional","affiliation":[{"name":"Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital , Sasebo, Nagasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University , Sapporo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Meerwein","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwei","family":"Bu","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Hirata","sequence":"additional","affiliation":[{"name":"AbbVie GK , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[{"name":"Division of Immunology and Rheumatology, Stanford University , Palo Alto, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"2026083106413577700_ref1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2026083106413577700_ref2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5114\/reum.2018.75523","article-title":"Cartilage and bone damage in rheumatoid arthritis","volume":"56","author":"Ostrowska","year":"2018","journal-title":"Reumatologia"},{"key":"2026083106413577700_ref3","first-page":"S9","article-title":"Update on methotrexate as the anchor drug for rheumatoid arthritis","volume":"71","author":"Pincus","year":"2013","journal-title":"Bull Hosp Jt Dis"},{"key":"2026083106413577700_ref4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026083106413577700_ref5","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026083106413577700_ref6","doi-asserted-by":"crossref","first-page":"7266","DOI":"10.1038\/s41598-021-86729-7","article-title":"Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics","volume":"11","author":"Maciejewski","year":"2021","journal-title":"Sci Rep"},{"key":"2026083106413577700_ref7","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s10067-016-3243-8","article-title":"Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire)","volume":"35","author":"Fatimah","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2026083106413577700_ref8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/1744666X.2018.1465409","article-title":"Prediction of response to methotrexate in rheumatoid arthritis","volume":"14","author":"Ling","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2026083106413577700_ref9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"key":"2026083106413577700_ref10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2026083106413577700_ref11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2026083106413577700_ref12","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"2026083106413577700_ref13","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026083106413577700_ref14","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"2026083106413577700_ref15","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"2026083106413577700_ref16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/14397595.2020.1847776","article-title":"Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-na\u00efve Japanese patients with rheumatoid arthritis: a sub-analysis of the phase 3 SELECT-EARLY study","volume":"31","author":"Takeuchi","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2026083106413577700_ref17","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026083106413577700_ref18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13075-024-03358-x","article-title":"Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial","volume":"26","author":"Vollenhoven","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2026083106413577700_ref19","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026083106413577700_ref20","first-page":"S100","article-title":"The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2026083106413577700_ref21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2026083106413577700_ref22","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026083106413577700_ref23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0950-3579(05)80189-X","article-title":"Methodological and statistical approaches to criteria development in rheumatic diseases","volume":"9","author":"Felson","year":"1995","journal-title":"Baillieres Clin Rheumatol"},{"key":"2026083106413577700_ref24","doi-asserted-by":"crossref","first-page":"vi16","DOI":"10.1093\/rheumatology\/kes281","article-title":"The new ACR\/EULAR remission criteria: rationale for developing new criteria for remission","volume":"51","author":"Bykerk","year":"2012","journal-title":"Rheumatology (Oxf)"},{"key":"2026083106413577700_ref25","first-page":"743","article-title":"How to read radiographs according to the Sharp\/van Der Heijde method","volume":"26","author":"Heijde","year":"1999","journal-title":"J Rheumatol"},{"key":"2026083106413577700_ref26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.1780350105","article-title":"Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis","volume":"35","author":"Heijde","year":"1992","journal-title":"Arthritis Rheum"},{"key":"2026083106413577700_ref27","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"2026083106413577700_ref28","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026083106413577700_ref29","doi-asserted-by":"crossref","first-page":"e001395","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"2026083106413577700_ref30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/mr\/roaf093","article-title":"The effectiveness and safety of subcutaneous methotrexate injection in Japanese patients with rheumatoid arthritis in a real-world setting","volume":"36","author":"Shimomura","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026083106413577700_ref31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/25785826.2024.2311763","article-title":"Safety risks of interstitial lung disease upon real-world usage of Janus kinase inhibitors and biologics for patients with autoimmune diseases: epidemiological study using nationwide electronic medical record database in Japan","volume":"47","author":"Yabuuchi","year":"2024","journal-title":"Immunol Med"},{"key":"2026083106413577700_ref32","doi-asserted-by":"crossref","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"2026083106413577700_ref33","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag031\/68023441\/roag031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/5\/705\/68023441\/roag031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/5\/705\/68023441\/roag031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:41:48Z","timestamp":1788172908000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/5\/705\/8650969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,4,10]]},"published-print":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roag031","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,4,10]]}}}